– NETHERLANDS, Utrecht – LAVA Therapeutics N.V. (NASDAQ: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the appointment of Karen Wilson to its Board of Directors as chair of the Audit Committee.
Ms. Wilson brings more than three decades of finance and leadership experience in the life sciences industry.
“I am delighted to welcome Karen to our Board of Directors,” said CEO, Stephen Hurly. “She joins us at an exciting time for our company as our first gamma-delta bsTCE candidates progress towards the clinic. Her deep experience leading finance organizations across both clinical- and commercial-stage public life science companies will be invaluable to LAVA as we advance our pipeline aimed at improving patient outcomes and creating value for our shareholders.”
About Karen Wilson
Karen Wilson is a biopharmaceutical finance executive and board member with experience in life science companies across finance, strategy, and risk management. She currently serves on the Board of Directors of Angion Biomedica, Connect Biopharma, and Vaxart, Inc. She was most recently SVP of Finance at Jazz Pharmaceuticals plc until September 2020 after serving as VP of Finance and Principal Accounting Officer. Before joining Jazz Pharmaceuticals in February 2011, Ms. Wilson served as VP of Finance and Principal Accounting Officer at PDL BioPharma, Inc. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, CFO of ViroLogic, Inc., CFO and VP of Operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP.
“With two candidates expected to enter the clinic in 2021 following a successful IPO, I am thrilled to join LAVA’s Board,” said Kate Wilson. “I am very excited about the potential of the LAVA platform to potentially transform the cancer treatment landscape. I look forward to working with the rest of the Board and management team to build on LAVA’s success and optimize the value of its unique gamma-delta T cell engager platform in oncology.”
Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.
About LAVA
LAVA Therapeutics N.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The company’s innovative approach leverages bispecific antibodies to activate Vγ9Vδ2 T cells upon binding to membrane-expressed tumor-associated antigens. Activated Vγ9Vδ2 T cells are engaged for direct, selective tumor cell killing. The company’s lead program, LAVA-051, is expected to enter a Phase 1/2a clinical study in hematologic malignancies in the first half of 2021. The company has established a highly experienced research and development team located in Utrecht, the Netherlands, and Philadelphia, USA.
For more information: https://lavatherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
